First human test for new lung scarring drug begins
NCT ID NCT04540770
Summary
This was the first study in humans to test the safety of an experimental drug called HuL001 for idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring. The study first gave single doses to 12 healthy volunteers to check for side effects, then gave multiple doses to 6 people with IPF. The main goal was to see how safe the drug was and how the body processed it, not to test how well it treated the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mackay Memorial Hospital
New Taipei City, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.